Company Encyclopedia
View More
name
Adherium Ltd.
ADR.AU
News
View More

16:23 ET Ikonopedia Expands Adoption of Risk Aware™ as Radiology Practices Prioritize Proactive Breast Cancer Risk Assessment

Ikonopedia announced significant growth in the adoption of its Risk Aware™ product, a web-based breast cancer risk assessment tool. Since its 2023 launch, over 50 healthcare organizations have adopted it, marking a 40% growth. The tool integrates the Tyrer-Cuzick model, aiding early detection and personalized care. Ikonopedia aims to make breast health tools accessible and efficient, enhancing patient care through proactive risk assessment.

prnewswire·
prnewswire·

Adherium Ltd. Announces Proposed Issue of 15 Million Securities

Adherium Ltd. announced a proposed issue of 15 million fully paid ordinary securities to be issued on November 25, 2025. This move aims to raise capital for ongoing operations and growth initiatives. Adherium operates in the healthcare industry, focusing on digital health technologies for monitoring respiratory conditions. The current market cap is A$9.69M, with a technical sentiment signal of 'Sell.'

Tip Ranks·
Tip Ranks·

Adherium Ltd. Announces Quotation of Over 494 Million Securities on ASX

Adherium Ltd. has announced the quotation of over 494 million ordinary fully paid securities on the Australian Securities Exchange (ASX). This move aims to enhance the company's capital structure and strengthen its market position, providing new growth opportunities in the digital health sector. Adherium focuses on digital health technologies, particularly in monitoring and managing respiratory conditions. The current market cap is A$9.63M.

Tip Ranks·
Tip Ranks·

Adherium to Host Investor Webinar on Recent Developments

Adherium Ltd. (AU:ADR) announced an investor webinar hosted by CEO Dawn Bitz to update stakeholders on recent developments and future outlook. This initiative reflects the company's commitment to transparency and may positively influence its market positioning. Adherium specializes in connected respiratory medical devices, particularly the Hailie® platform, which aids in monitoring medication adherence. Current market cap stands at A$7.45M, with a technical sentiment signal indicating a 'Sell' recommendation.

Tip Ranks·
Tip Ranks·

Adherium Ltd. Announces Promising Interim Results from iCARE Study with Hailie® Smartinhaler®, Showing Record Adherence in COPD and Asthma Care

Adherium Ltd. has announced promising interim results from the iCARE study, which investigated chronic respiratory care using its Hailie® Smartinhaler® technology. The study, involving 4,000 devices and 2,500 COPD and asthma patients, showed significant adherence improvements and potential cost savings. Nearly 850 participants demonstrated high engagement levels. Detailed results are expected later this year, emphasizing the technology's potential to enhance patient outcomes and establish a scalable, value-based care model.

Reuters·
Reuters·